The goal of this application is to enhance the process of improving the treatment of cancer patients through cooperative clinical trials. Randomized clinical trials provide the best evidence concerning the effectiveness of different forms of therapy; consequently the National Cancer Institute (NCI) has funded clinical trials groups dedicated to developing and conducting these studies. It is now clear that, although these groups can often undertake important trials independently, in many cases cooperation among them is needed to answer key questions expeditiously. Thus, formal mechanisms for developing and conducting """"""""intergroup"""""""" trials have been implemented and a number of such studies have been completed. The National Cancer Institute of Canada, an agency funded by donations to the Canadian Cancer Society, supports a clinical trials group (NCIC CTG) which has functions and a structure similar to US groups. Like US groups, the NCIC CTG has conducted numerous studies of its own and has made important contributions to the development of current standards of care. The NCIC CTG has also been active in intergroup trials, both as a participating and as a """"""""lead"""""""" group. The immediate purpose of this application is to seek support for continued and enhanced participation of the NCIC CTG in US intergroup studies with the following specific aims: 1. To contribute patient enrolment, data management resources, and high quality data to intergroup trials sponsored by NCI; 2. To provide scientific input into the development design and conduct of NCI intergroup trials; and 3. To provide leadership and coordination resources for some NCI intergroup trials. Without the funding sought in this application, the NCIC CTG can, at best, make a limited contribution to the important research effort represented by intergroup trials. With it, the Group can help both in defining the questions to be addressed and in ensuring they are answered quickly and correctly.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Queen's University at Kingston
Zip Code
K7 3-N6
Lemieux, Julie; Brundage, Michael D; Parulekar, Wendy R et al. (2018) Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. J Clin Oncol 36:563-571
Francis, Prudence A; Pagani, Olivia; Fleming, Gini F et al. (2018) Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med 379:122-137
Beltran, Himisha; Wyatt, Alexander W; Chedgy, Edmund C et al. (2017) Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res 23:6802-6811
Saha, Poornima; Regan, Meredith M; Pagani, Olivia et al. (2017) Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol 35:3113-3122
Regan, M M; Walley, B A; Francis, P A et al. (2017) Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 28:2225-2232
Agarwala, Sanjiv S; Lee, Sandra J; Yip, Waiki et al. (2017) Phase III Randomized Study of 4 Weeks of High-Dose Interferon-?-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Gro J Clin Oncol 35:885-892
Yerushalmi, R; Dong, B; Chapman, J W et al. (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28:1560-1568
Sonnenblick, Amir; Agbor-Tarh, Dominique; Bradbury, Ian et al. (2017) Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. J Clin Oncol 35:1421-1429
Haas, Naomi B; Manola, Judith; Dutcher, Janice P et al. (2017) Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol 3:1249-1252
Ribi, Karin; Bernhard, Jürg; Luo, Weixiu et al. (2016) Reply to F. Tomao et al. J Clin Oncol 34:4189-4190

Showing the most recent 10 out of 79 publications